Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $5.36 down -0.92% from its previous closing price of $5.41. In other words, the price has decreased by -$0.92 from its previous closing price. On the day, 12.06 million shares were traded. RXRX stock price reached its highest trading level at $5.58 during the session, while it also had its lowest trading level at $5.35.
Ratios:
For a deeper understanding of Recursion Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.58. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 27 ’25 when Gibson Christopher sold 138,574 shares for $6.04 per share. The transaction valued at 836,987 led to the insider holds 1,117,450 shares of the business.
Gibson Christopher bought 138,574 shares of RXRX for $836,987 on Mar 27 ’25. On Mar 05 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $6.58 each. As a result, the insider received 131,600 and left with 1,256,024 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2327054848 and an Enterprise Value of 1892760192. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.02 while its Price-to-Book (P/B) ratio in mrq is 2.52. Its current Enterprise Value per Revenue stands at 29.302 whereas that against EBITDA is -3.228.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.93, which has changed by -0.111111104 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -0.18%, while the 200-Day Moving Average is calculated to be -13.65%.
Shares Statistics:
For the past three months, RXRX has traded an average of 27.88M shares per day and 20826450 over the past ten days. A total of 425.48M shares are outstanding, with a floating share count of 332.14M. Insiders hold about 23.50% of the company’s shares, while institutions hold 56.61% stake in the company. Shares short for RXRX as of 1752537600 were 115527481 with a Short Ratio of 4.14, compared to 1749772800 on 120075634. Therefore, it implies a Short% of Shares Outstanding of 115527481 and a Short% of Float of 28.599999999999998.
Earnings Estimates
The current market rating for Recursion Pharmaceuticals Inc (RXRX) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.24 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.29 and -$1.8 for the fiscal current year, implying an average EPS of -$1.55. EPS for the following year is -$1.23, with 9.0 analysts recommending between -$0.81 and -$1.6.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $19.36M this quarter.It ranges from a high estimate of $23.9M to a low estimate of $16M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $26.08MFor the next quarter, 5 analysts are estimating revenue of $17.7M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $16M.
A total of 7 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $95.5M, while the lowest revenue estimate was $65.97M, resulting in an average revenue estimate of $74.86M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $96.71M in the next fiscal year. The high estimate is $208.4M and the low estimate is $45M.
